Trump administration to pilot covering obesity drugs
A combination image shows Zepbound’s injection item, Eli Lilly’s weight loss medication and Wegovy boxes made by Novo Nordisk.
Hollie Adams | Reuters
A version of this article was first published in the CNBC’s healthy return bulletin, which brought the latest health news directly to your box. Subscribe here To get future prints.
Once upon a time, the Trump administration may give a reason to celebrate some drug producers.
Trump Management plans to try to cover expensive weight loss medications under the post of Medicare and Medicaid, Washington reported Friday. This plan can expand access to millions of Americans with obesity that cannot meet at the moment. Novo NordiskWegovy and Hand LillyZepbound, which costs approximately $ 1,000 per month before the fuse, is GLP-1 drugs that break box office records.
CNBC said in a statement about the plan, the Ministry of Health and Human Services said that the whole scope of the drug has been “cost-cost review”. Medicare and Medicaid Service Centers “He does not comment on potential models or coverage.”
The reported plan – if it ultimately comes into force – Eli Lilly, Novo Nordisk and many Americans would have a great win.
The scope of the acne insurance of obesity drugs continues to be the biggest obstacle of accessing for patients – and for two pharmaceutical giants, wider purchase and income increase is drowning. Many health plans, including Medicare, cover GLP-1s for diabetes treatment, but not obesity. Medicaid scope of obesity drugs Limited and depends on the situationHealth Policy According to the Research Organization KFF.
However, it is important to remember that this plan is not exactly new.
In November, Biden management suggested that Medicare and Medicaid cover obesity treatments, which will expand roughly access. 3.4 million medicare beneficiaries and approximately 4 million Medicaid buyers. According to a congress analysis, the proposal would be controversial at that time, because taxpayers will cost $ 35 billion in the next decade.
The Trump administration left this proposal in April, but he said in the future he could re -evaluate the scope of these drugs.
Let’s get into the newest repetition of the plan.
In accordance with the reported pilot plan of the Trump administration, the state Medicaid programs and Medicare Chapter D plans were able to voluntarily choose Özempic, Wegovy, Mounjaro and Zepbound for patients for “weight management” purposes. This is according to several centers for medicare and medicaid services documents obtained by Post.
Post is expected to start for Medicaid and Medicare plans for Medicaid and January 2027 in April 2026.
Mizuho Health Capital Strategist Jared Holz, as a note to customers on Friday, is not clear how the plan will play exactly. Holz said that the government expects the government to put some coverage parameters related to factors such as age, body weight, body mass index and other comorbidities or chronic health conditions that exist together.
He also said that the pricing of the drugs would be “a big issue”. Holz said the government expects to pay less than existing drug prices. But to have it He said that the scope will expand access and help to increase higher sales volumes.
Another factor to consider is how much the government wants to destroy as a compound pharmacies that are allowed to sell cheaper, unapproved versions of GLP-1s in rare cases. This is strongly opposed to GLP-1s, since the pharmaceutical industry is not controlled by the regulators and in some cases is sold illegally.
Holz said that the complaints of the industry combined to the government have not been met with a widespread closure so far.
In general, however, Holz reported that Trump administration’s desire to think about covering obesity drugs was “a slight positive according to industrial sensitivity”.
Eli Lilly, Novo Nordisk and other drug producers are definitely a clean breath – Amgen– Roche– Astrazeneca And Pfizer – This hopes to present his own obesity medications to the market.
The last six months has been smooth for the wider industry: Trump administration called for calls for overhauling federal health institutions by drug producers to reduce US pharmaceutical prices, and now apply comprehensive tariffs on the pharmaceutics imported to the country every day.
We will continue to watch to see if this plan is implemented, so continue watching us for our scope!
Feel free to send any clues, suggestions, story ideas and data to Annika. Annikakim.constantino@nbcuni.com.
Latest in Health Service: Earning Season Saw Medicare Advantage Players Places to Changed
Unitedhealth Group Inc. On April 21, 2025, the signage at the base of the New York Stock Exchange.
Michael Nagle | Bloomberg | Getty Images
After notifying the second flat earnings, Unitedhealth Group CFO replaced John Rex and completed the swelling of the manager. Medicare promised to return to profitability and recover the Investor Foundation in Advantage.
Almost two years ago CVS Health Under pressure, the profits in the company’s Eetna Health Insurance Department were torpedo by Low Medicare Advantage Star quality ratings.
This week, the CVS defeated the Power of the MA program and brought up the agenda. CEO David Joyner, now he went to work for a year, said he felt good about the return in Eetna and Medicare. Furthermore, the company has seen its market share gains in stores thanks to the winning of Rite AID customers.
Humana, similarly, made progress on the return, but CFO Celeste Mellet told me that all insurance companies are struggling with pricing plans for next year among high medical costs. Mellet, which is currently a major cost driver, told CNBC, oncology medicines, because some expensive treatments are now used in combination.
The next real memory for Medicare Advantage players will come for the next six weeks – they will learn the fate of star ratings for their 2026 plans.
Read more than Bertha Coombs from CNBC here.
Latest in Health Service Technology: Marc Harrison took the role of a strategic consulting in General Catalyst
CNBC, long -term health manager Marc Harrison resigned as General Catalyst’s health security transformation company or CEO of Hatco’s CEO and became a strategic consultant.
The venture capital company brought Harrison and announced the formation of Hatco in 2023. a version At that time, General Catalyst said that the company would work close to the health system partners and will eventually obtain and operate its own health system.
Months later Hatco announced Plans to purchase Summa Health, a non -profit integrated health system in Northeast Ohio. Under New structureSumma will be a non -profit organization, and General Catalyst will offer new technology solutions that aim to make care more accessible and affordable.
Buying a health system, an unprecedented move and agreement in the initiative industry has not been well received by some members of the Ohio community. Hundreds of He signed a petition He invites Summa to be a non -profit organization and to stop negotiations with Hatco.
Ohio Attorney General Dave Yost conditionally approved In June, the agreement summarized only a number of “applicable commitments” as part of the agreement. For example, HATCO will have to inform the Chief Public Prosecutor’s Office for operations that can trigger antitröst concerns for 10 years.
In the late 1980s, Harrison went to the Faculty of Medicine and spent most of his career in health systems as the CEO of Intermountain Healthcare. General Catalyst said that Harrison’s CEO of Harrison’s CEO will continue to provide clinical insights and would remain connected to the ecosystem in the new role.
“For both Marc and for us, the role of Marc’s role for both Marc and us has become increasingly clear that it will be realized as a strategic consultant to Hemanja, while the role of Marc is the best.” He said.
Sözcü said that General Catalyst was promoted to the president of Hatco, the head of the health security ecosystem. Summa will lead the company’s daily work with Health Leadership.
General Catalyst also appointed former Massachusetts Health and Human Services Secretary Kate Walsh to the board of Hatco. In addition, he will serve as the Chairman of the Board of Directors at Summa Health after the transaction is closed.
“We are grateful to help us come to this point in Hatco’s evolution as Marc’s leadership and co -partner and CEO, and we are looking forward to taking advantage of the invaluable point of view as we continue to progress.” He said.
Read more of CNBC’s scope for Hatco’s acquisition of Summa Health.
Feel free to send any clues, suggestions, story ideas and data to Ashley at Ashley.capoot@nbcuni.com.
